Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

13.16
+0.58004.61%
Volume:2.79M
Turnover:37.58M
Market Cap:1.87B
PE:-3.40
High:13.79
Open:13.51
Low:13.02
Close:12.58
52wk High:46.81
52wk Low:6.36
Shares:142.26M
Float Shares:118.00M
Volume Ratio:1.74
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8694
EPS(LYR):-3.3716
ROE:-61.32%
ROA:-35.45%
PB:3.28
PE(LYR):-3.90

Loading ...

Dyne Therapeutics Raised to Strong Buy From Outperform by Raymond James

Dow Jones
·
Yesterday

Raymond James Upgrades Dyne Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $35 From $31

MT Newswires Live
·
Yesterday

Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James

TIPRANKS
·
Yesterday

Bernstein Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Aug 22

Bernstein Remains a Hold on Dyne Therapeutics (DYN)

TIPRANKS
·
Aug 18

Dyne Therapeutics Advances DMD Treatment with DYNE-251 Study

TIPRANKS
·
Aug 14

Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer

TIPRANKS
·
Aug 06

Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating

TIPRANKS
·
Aug 05

Stock Track | Dyne Therapeutics Soars 5.37% Pre-market on FDA Breakthrough Therapy Designation for DMD Treatment

Stock Track
·
Aug 04

Stock Track | Dyne Therapeutics Soars 5.37% Pre-market on FDA Breakthrough Therapy Designation for DMD Treatment

Stock Track
·
Aug 04

Dyne Therapeutics Secures FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy, Targeting Accelerated Approval in 2026

Reuters
·
Aug 04

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for Dyne-251 in Duchenne Muscular Dystrophy (Dmd)

THOMSON REUTERS
·
Aug 04

Dyne Therapeutics Inc - Data From Deliver Cohort Expected Late 2025, Bla Early 2026

THOMSON REUTERS
·
Aug 04

Stifel Nicolaus Sticks to Their Buy Rating for Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 31

Dyne Therapeutics: Strategic Advancements and Financial Stability Drive Buy Rating

TIPRANKS
·
Jul 30

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Benzinga
·
Jul 30

Dyne Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 29

RBC Trims Price Target on Dyne Therapeutics to $23 From $25, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 29

U.S. RESEARCH ROUNDUP-Blackline, Cadence Design Systems, Coinbase Global

Reuters
·
Jul 29

Dyne Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $38 From $50

THOMSON REUTERS
·
Jul 29